Evaluation of the serum metabolome of patients with alkaptonuria before and after two years of treatment with nitisinone using LC-QTOF-MS

Andrew S. Davison1,2 | Brendan P. Norman2 | Gordon A. Ross3 |
Andrew T. Hughes1,2 | Milad Khedr1,2 | Anna M. Milan1,2 | James A. Gallagher2 |
Lakshminarayan R. Ranganath1,2

1Department of Clinical Biochemistry and Metabolic Medicine, Liverpool Clinical Laboratories, Royal Liverpool University Hospitals Trust, Liverpool, UK
2Musculoskeletal Biology I, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool Health Partners, Liverpool, UK
3Agilent Technologies, Cheadle, UK

Correspondence
Andrew S. Davison, Department of Clinical Biochemistry and Metabolic Medicine, Liverpool Clinical Laboratories, Royal Liverpool University Hospitals Trust, Liverpool, L7 8XP, UK.
Email: andrew.davison@rlbuht.nhs.uk

Funding information
Research Trainees Coordinating Centre, Grant/Award Number: DRF-2014-05-009; National Institute for Health Research, Grant/Award Number: DRF-2014-05-009

Communicating Editor: Johannes Häberle

Abstract
Background: The homogentisic acid-lowering therapy nitisinone is being evaluated for the treatment of alkaptonuria (AKU) at the National Centre for AKU. Beyond hypertyrosinemia, the wider metabolic consequences of its use are largely unknown. The aim of this work was to evaluate the impact of nitisinone on the serum metabolome of patients with AKU after 12 and 24 months of treatment.

Methods: Deproteinized serum from 25 patients with AKU (mean age ±SD 51.1 ± 14.9 years, 12 male) was analyzed using the 1290 Infinity II liquid chromatography system coupled to a 6550 quadrupole time-of-flight mass spectrometry (Agilent, UK). Raw data were processed using a batch targeted feature extraction algorithm and an accurate mass retention time database containing 469 intermediary metabolites (MW 72-785). Matched entities (±10 ppm theoretical accurate mass and ±0.3 minutes retention time window) were filtered based on their frequency and variability (<25% CV) in group quality control samples, and repeated measures statistical significance analysis with Benjamini-Hochberg false discovery rate adjustment was used to assess changes in metabolite abundance.

Results: Eight metabolites increased in abundance (log2 fold change [FC] 2.1-15.2, P < .05); 7 of 8 entities were related to tyrosine metabolism, and 13 decreased in abundance (log2 FC 1.5-15.5, P < .05); including entities related to tyrosine (n = 2), tryptophan (n = 3), xanthine (n = 2), and citric acid cycle metabolism (n = 2).

Abbreviations: 3-(4-HPLA), 3-(4-hydroxyphenyl)lactic acid; 3-(4-HPPA), 3-(4-hydroxyphenyl)pyruvic acid; 4-HBA, 4-hydroxybenzaldehyde; 4-HPA, 4-hydroxyphenylacetate; AKU, alkaptonuria; AMRT, accurate mass retention time; FAH, fumarylacetoacetate hydratase; HGA, homogentisic acid; HGD, homogentisate-1,2-dioxygenase; HPPD, hydroxyphenylpyruvic acid dioxygenase; HT1, hereditary tyrosinaemia type 1; I-3-L, indole-3-lactate; I-3-P, indole-3-pyruvate; MPP, mass profiler professional; MS/MS, tandem mass spectrometry; NAC, National Alkaptonuria Centre; QC, quality control.

Andrew S. Davison and Brendan P. Norman are joint first authors.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2019 The Authors. Journal of Inherited Metabolic Disease published by John Wiley & Sons Ltd on behalf of SSIEM.
Conclusions: Evaluation of the serum metabolome of patients with AKU showed a significant difference in the abundance of several metabolites following treatment with nitisinone, including a number that have not been previously reported; several of these were not related to the tyrosine metabolic pathway.

Synopsis
Nitisinone therapy has a significant impact on several metabolites beyond the tyrosine metabolic pathway, several of which appear to be related to the redox state of the cell.

KEYWORDS
alkaptonuria, metabolomics, nitisinone, tyrosine

1 | INTRODUCTION

Alkaptonuria (AKU, OMIM: 203500) is a rare autosomal recessive disorder of tyrosine metabolism resulting from a defect in homogentisate-1,2-dioxygenase (HGD, E.C.1.12.11.5), which leads to a marked increase in the circulating concentration of homogentisic acid (HGA).\(^1\) The pathological hallmark of AKU is “ochronosis,” which is a consequence of the deposition of a dark pigment in connective tissue, mainly cartilage, which alters its physicomechanical properties. The exact composition and structure of this pigment is unknown, but is known to result from the accumulation of HGA (Figure S1).\(^2\)

Treatment options for AKU are conservative in large focusing on supportive and palliative measures.\(^2\) The HGA lowering agent nitisinone (Figure S1) has been shown to completely prevent ochronosis in AKU mice\(^3\) and is being evaluated as a potential treatment in AKU patients\(^1,4-8\); it is however not without its own challenges as it is well documented to result in significant hypertyrosinemia in AKU\(^1,4-10\) and hereditary tyrosinaemia type 1 (HT1, OMIM: 276700).\(^11-13\) The consequences of this are largely unknown in AKU; in HT1 it has been suggested this may contribute to the neurodevelopmental delay that is frequently observed in children treated with nitisinone.\(^14\) Several mechanisms have been proposed for this including altered metabolism of the monoamine neurotransmitters.\(^15\) Davison et al.\(^16,17\) demonstrated in a cohort of AKU patients that nitisinone therapy resulted in altered urinary excretion of dopaminergic and serotoninergic neurotransmitter metabolites. However, these findings are limited as they are not a direct reflection of neurotransmitter metabolism in the central nervous system. A recent study in an animal model of HT1 suggested that the disease itself and not treatment with nitisinone is likely to be responsible for slower learning and altered behavior in mice.\(^18\)

Recently, changes in the urine metabolome of an AKU mouse model and patients with AKU treated with nitisinone were reported.\(^19\) This study demonstrated novel changes in the tyrosine metabolic pathway, and unexpectedly in tryptophan and purine metabolism. While these changes in the urine metabolome provide insight into how nitisinone alters metabolism, one may postulate that changes observed in the serum are more relevant as they are a more direct reflection of internal homeostasis. Gertsman et al.\(^20\) reported on the impact of nitisinone therapy on the serum metabolome of patients with AKU. In addition to the expected decrease in HGA and increase in tyrosine, significant increases in acetyl- and γ-glutamyltyrosine were also observed. In a separate publication\(^21\) in the same cohort of patients, novel disturbances in tryptophan metabolism were reported.

Herein for the first time we report the impact of nitisinone (2 mg daily) therapy on the serum metabolome in the largest cohort of AKU patients to date over a 2-year period at the National AKU Centre (NAC) in the United Kingdom.

2 | MATERIALS AND METHODS

2.1 | Reagents

Water for mobile phases was purified in-house (DIRECT-Q 3UV Millipore water purification system). Methanol, acetonitrile, and isopropanol were purchased from Sigma-Aldrich (Dorset, UK). Formic acid and ammonium formate were obtained from Biosolve (Netherlands) and Fisher Scientific (Germany), respectively. All reagents were liquid chromatography (LC)-mass spectrometry (MS) grade. Acetyl-tyrosine was purchased from Sigma-Aldrich, UK.

3 | PATIENTS AND SERUM SAMPLE COLLECTION

3.1 | Ethical approval

Data collection and sample analyses at the NAC have approval from the Royal Liverpool and Broadgreen University Hospital
Trusts Audit Committee (Audit no. ACO3836), this approval includes the use of patient data and biological material for metabolomics evaluation. As data and samples were collected as part of the clinical service, ethical approval was not required. Patients are informed verbally and through patient information leaflets about the clinical and research activities of the NAC and are informed that data may be used for publication. For a detailed protocol see Milan et al.5

3.2 Sample collection

Serum samples (S-monovette; Sarstedt, Germany) were collected from patients after an overnight fast (≥8 hours). Patients’ dietary intake of protein was managed through a 7-day food diary by a combination of lower protein in diet and phenylalanine/tyrosine-free meal exchanges. Samples were centrifuged at 1500g for 10 minutes at 4°C; and then deproteinized with perchloric acid (60% 5.8 M; 1:10, perchloric acid:serum), vortexed and centrifuged at 1500g for 10 minutes. Supernatant was stored at −20°C until analysis.

4 PATIENT AND QUALITY CONTROL SAMPLE PREPARATION

Patient samples were prepared by diluting 150 μL of serum with 450 μL of deionized water (DIRECT-Q 3 UV Millipore water purification system). Diluted samples were then transferred into a 96-well plate which was then agitated on a plate shaker (MTS 2/4 m IKA, Germany) at 600 rpm for 10 minutes.

Patient group quality control (QC) samples were produced by adding 50 μL of each patient sample into a single pool. In total four group QC pools were made ([a] baseline, [b] 12-months, [c] 24-months, and [d] overall—containing serum from all patients and visits; this acted as a system QC). QC samples were prepared as per patient samples.

The analytical sequence of samples was performed as per published guidance. Each run commenced with 20 replicate injections of the overall pooled sample to condition the system. The order of individual samples was randomized computationally. Pooled samples were interspersed throughout the analytical sequence every tenth injection.

5 ANALYTICAL METHOD

5.1 Chromatographic conditions

Liquid chromatography was performed on an Agilent 1290 Infinity II LC system. An Atlantis dC18 column (3.0 × 100 mm, 3 μm, Waters, UK) was maintained at 60°C with a flow rate of 0.4 mL/min. Mobile phases were (A) water and (B) methanol both containing 5 mmol/L ammonium formate and 0.1% formic acid. The elution gradient started at 5% mobile phase B at 0-1 minute increasing linearly to 100% B by 12 minutes, held at 100% B until 14 minutes, returning to 95% A for 5 minutes to recondition the column. Injection volume was 1 μL.

5.2 Quadrupole time-of-flight MS conditions

An Agilent 6550 quadrupole time-of-flight MS (QTOF-MS) equipped with a dual jet stream electrospray ionization source was operated in 2 GHz mode, over the mass range of 50-1700, in negative and positive polarities. A reference mass correction solution was continually infused at a flow rate of 0.5 mL/min via an external isocratic pump (Agilent, UK) for constant mass correction (see Supporting Information 1 for additional details of QTOF-MS operating parameters and composition of reference ion solution).

6 METABOLITE IDENTIFICATION, DATA QC, AND STATISTICAL ANALYSES

Metabolite identification was carried out using an established accurate mass retention time (AMRT) database to match chemical entities. The database included theoretical accurate mass, measured retention time, and empirical formula. This was modified to include acetyl-tyrosine, γ-glutamyltyrosine, and indole-3-lactate (I-3-L). AMRT data for acetyl-tyrosine were verified following the analysis of an analytical standard. AMRT data for γ-glutamyltyrosine and I-3-L were based on the elution time associated with theoretical monoisotopic mass of each compound and were not verified using an analytical standard. Data and statistical analyses were performed using the MassHunter software suite (Agilent, UK). For additional details on data and statistical analyses, see Supporting Information 1.

7 RESULTS

Twenty-five patients (13 female, mean age[±SD] 55.3[15.3] years [range 22-75]; 12 male, mean age 44.2[15.8] years [range 22-70]) were included at baseline and after treatment with nitisinone at 12 and 24 months.

Raw data from LC-QTOF-MS analysis showed that retention time and accurate mass ranges were 1.15-13.93 minutes and 75.0318-730.5955 Da, in positive and 1.03-14.67 minutes and 75.0318-722.6247 Da in negative polarity, respectively. Principal components analysis (Figure 1) showed clear separation between the AMRT-matched profiles of AKU patients pre- vs post-nitisinone therapy.

One hundred fifty-one of 469 and 249 of 469 metabolites were aligned across all samples in positive and negative polarities (for matched compounds see Table S2), respectively, at baseline, and after nitisinone treatment at 12 and
24 months. After filtering entities based on their frequency and variability across replicate injections of pooled QC samples from each experimental group, 123 and 209 entities were retained from positive and negative polarity profiling experiments, respectively. Of these, 60 and 121, respectively, were shown to be significantly different \( (P < .05) \) following nitisinone therapy. Those with a \( \log_2 \) fold change (FC) \( >2 \) at 12 and/or 24 months are summarized in Table 1. Applying this cut-off, eight \( (6.5\%) \) entities were considered to increase in abundance and 13 \( (10.7\%) \) decrease in abundance.

Nine \( (43\%) \) of the 21 metabolites that were affected following treatment with nitisinone relate to tyrosine metabolism. Many of the other metabolites that had altered abundance following nitisinone therapy did not follow a clear theme apart from tryptophan, citric acid cycle, and purine/pyrimidine metabolism.

### 8 | DISCUSSION

Over the last two decades, there have been several reports on the use of nitisinone to treat AKU. Its inhibition of HPPD (Figure S1) has been shown to dramatically reduce the circulating concentration of HGA,\(^1\)\(^4\)-\(^8\) but leads to marked hyper-tyrosinemia.\(^1\)\(^4\)-\(^10\) Beyond hyper-tyrosinemia, there is very little reported on the biochemical consequences of nitisinone therapy. Herein, we report the impact of nitisinone therapy on the serum metabolome, using LC-QTOF-MS and a validated strategy to identify metabolites using an AMRT database developed in-house.\(^1^9\) This study is unique as it includes the largest cohort of patients with AKU to date, taking a 2 mg daily dose of nitisinone over 24 months. In addition, as it is based on the analysis of serum it is a better reflection of the impact of nitisinone on internal homeostasis.

This study confirms previous reports that nitisinone treatment in AKU results in a marked reduction in serum HGA and increase in tyrosine. In addition, a significant increase in 3-(4-hydroxyphenyl)lactate (3-(4-HPLA)) was observed. Unexpectedly 3-(4-hydroxyphenyl)pyruvate (3-(4-HPPA)), the metabolite immediately proximal to the site of action of nitisinone, was not increased (Figure S1). The marked increase in HPLA is an expected consequence of nitisinone therapy, but has not been reported in serum. There is an equilibrium between 3-(4-HPPA) and 3-(4-HPLA) (Figure S1) and it is likely that the reason for only observing significant increases in latter is that the sample pH shifted the equilibrium position to favor its formation. This pattern has been previously reported\(^1^9\) in a study that reported on the urine metabolome of patients with AKU treated with nitisinone; a 84- and 3.3-fold (raw FC) increase in 3-(4-HPLA) and 3-(4-HPPA) were reported, respectively.

Marked increases in the tyrosine conjugates acetyl-tyrosine and \( \gamma \)-glutamyltyrosine were also observed. The \( \log_2 \) FC observed was very similar for tyrosine and \( \gamma \)-glutamyltyrosine, but that of acetyl-tyrosine was markedly higher. The latter suggests that an equilibrium shift between tyrosine and acetyl-tyrosine may exist, but not for tyrosine and \( \gamma \)-glutamyltyrosine. Norman et al.\(^1^9\) showed that urinary tyrosine was significantly higher than acetyl-tyrosine and \( \gamma \)-glutamyltyrosine in a cohort of AKU patients on 2 mg daily of nitisinone supporting that an equilibrium shift between tyrosine and tyrosine conjugates exists. In contrast, Gertsman et al.\(^2^0\) reported a proportional increase in plasma tyrosine, acetyl-tyrosine and \( \gamma \)-glutamyltyrosine following nitisinone suggesting there is no equilibrium shift. While direct comparisons between the magnitudes of FC cannot be made as herein we report \( \log_2 \) FC, the proportions of metabolites are clearly different between the two studies. This may be due to the small number of patients in the study reported by Gertsman et al.\(^2^0\) and that a 2 mg dose was used only in our study. Nonetheless, our findings support that nontraditional metabolic pathways are active in the face of tyrosine excess.

The elevated \( \gamma \)-glutamyltyrosine suggests that glutathione metabolism and the redox state of cell\(^2^3\)\(^2^4\) are altered following treatment with nitisinone. This is of particular importance to AKU as elevated HGA is thought to lead to a pro-oxidant environment where “soluble melanins” are formed.\(^2^5\) Increasing evidence to support HGA-induced oxidative stress has been reported in vitro in serum\(^2^6\) and cellular models,\(^2^7\) and
for a recent review on oxidative stress and its contribution to the mechanisms of the ochronotic process, see Ref. 29. One may postulate that treatment with nitisinone reduces the burden on the glutathione cycle improving glutathione availability. In turn, this may enable transfer of the glutamyl moiety from glutathione to tyrosine, via the action of $\gamma$-glutamyl-transpeptidase23,24 to form $\gamma$-glutamyltyrosine.

Interestingly, this study also revealed a marked decrease in the citric acid cycle metabolites $\alpha$-ketoglutaric and succinic acid, the keto acids of $\alpha$-ketoglutarate and succinate, following nitisinone. In this study, glutamine levels did not change, thus one may hypothesize that glutamate formed from glutamine is preferentially converted to glutathione and not $\alpha$-ketoglutaric and succinic acid (Figure 2). The significance of this is not understood and requires further investigation.

The increase in acetyl-tyrosine is unknown, but has been reported in serum20 and urine19 of AKU patients treated with nitisinone. It has also been observed in the urine of patients with hereditary tyrosinaemia type 2 (OMIM: 276600).30 One may postulate that acetyl-tyrosine represents a more efficient way to eliminate the excess tyrosine from the body as it is more water soluble than tyrosine. Interestingly acetyl-tyrosine has also been reported as an additive to foodstuffs given to patients on nutritional support.31

4-Hydroxyphenylacetate (4-HPA), 4-hydroxybenzaldehyde (4-HBA), and benzaldehyde were increased significantly following treatment with nitisinone; these have not previously reported in the serum metabolome of patients with AKU following nitisinone treatment. 4-HPA has been reported in urine following treatment with nitisinone.19 4-HPA is generated from gut microbiota32; one may hypothesize that the increase observed herein resulted from less oxidative stress following nitisinone, which increased microbiotic metabolism. This is the first report in humans, but has been seen previously observed in a rat model of oxidative stress.32

The increase in 4-HBA has been reported in the urine of patients with AKU following nitisinone,19 but the decrease in benzaldehyde has never been observed. The significance of both entities is uncertain. 4-HBA is a naturally occurring compound that originates from the saprophytic perennial

**Table 1** Serum metabolite changes identified post-nitisinone therapy at 12 and 24 months in patients with AKU using an in-house AMRT database

| Compound                          | Log<sub>2</sub> FC | Abundance | Metabolic process/pathway affected |
|-----------------------------------|--------------------|-----------|-----------------------------------|
| Glycocholate                      | 12.7 12.7          | Down      | Bile acid                         |
| Succinic acid                     | 11.4 11.4          | Down      | Citric acid cycle                 |
| $\alpha$-Ketoglutaric acid        | 10.0 10.0          | Down      | Citric acid cycle                 |
| Trans-4-hydroxyproline            | 15.5 15.5          | Down      | Collagen                          |
| Homoserine                        | 12.5 12.5          | Down      | Methionine/cysteine               |
| Mevalonolactone                   | 10.7 10.7          | Down      | Steroid                          |
| l-Allothreonine                   | 11.8 11.8          | Up        | Threonine                         |
| Trigonellite                      | 12.8 12.8          | >.001     | Tryptophan                        |
| 4-Quinolinecarboxylic acid        | 8.3 8.3            | >.001     | Tryptophan                        |
| Indole-3-lactate                  | 2.1 2.3            | >.001     | Tryptophan                        |
| 4-Hydroxyphenylacetate            | 4.2 5.4            | >.001     | Tyrosine                          |
| Benzaldehyde                      | 6.9 6.9            | >.001     | Tyrosine                          |
| Homogentisate                     | 4.0 5.0            | >.001     | Tyrosine                          |
| 4-Hydroxybenzaldehyde             | 14.4 14.4          | >.001     | Tyrosine                          |
| l-N-Acetyl-tyrosine               | 15.5 15.2          | >.001     | Tyrosine                          |
| $\gamma$-L-Glutamyl-tyrosine      | 3.2 3.0            | >.001     | Tyrosine                          |
| 3-(4-Hydroxyphenyl)lactate        | 6.4 6.4            | >.001     | Tyrosine                          |
| l-Tyrosine                        | 2.7 2.7            | >.001     | Tyrosine                          |
| Mandelic acid                     | 12.6 12.0          | >.001     | Tyrosine                          |
| Inosine                           | 10.8 10.8          | >.001     | Purine                            |
| Uridine                           | 2.1 1.5            | >.001     | Pyrimidine                        |

*Note:* Abundance expressed as log<sub>2</sub> FC compared to baseline (pre-nitisinone treatment). Log<sub>2</sub> FC included if >2 at 12- and or 24-months.

*Abbreviation:* AMRT, accurate mass retention time.
Gastrodia elata.\textsuperscript{33} Recent studies have reported the therapeutic effects of benzaldehydes in a number of areas including wound healing, cancer, vascular disease, and renal disease.\textsuperscript{34-37} In the context of AKU, the significance of 4-HBA and benzaldehyde are unknown and require further investigation. One may speculate that they relate to the benzoquinones, proposed as intermediates in the formation of ochronotic pigment observed in AKU.\textsuperscript{19}

Mandelic acid was also increased following treatment with nitisinone, which has been reported previously.\textsuperscript{19} The significance of this is uncertain, but urinary elevation has previously been observed in patients with PKU on a phenylalanine-restricted diet.\textsuperscript{38}

The “off target effects” of any drug are essential when considering its suitability in treating a patient.\textsuperscript{39} Nitisinone therapy in AKU and HT1 has long been associated with altered-tyrosine metabolism, and so can be considered a “targeted effect.” More recently off targets effects of nitisinone have been reported due to its impact on tryptophan metabolism. A decrease in 5-hydroxyindoleacetic acid (serotonin metabolite) has been reported in the cerebral spinal fluid and urine of patients with HT1\textsuperscript{15} and AKU,\textsuperscript{16,17} respectively. Serum tryptophan itself has been shown not to change following treatment with nitisinone\textsuperscript{9}; in contrast, urinary tryptophan has been shown to decrease.\textsuperscript{19} These differences may be explained by the fact that tryptophan is highly protein bound (~90%-95\%)\textsuperscript{40} and measurement in serum reflects total tryptophan and urinary tryptophan reflects free tryptophan. The biologically active fraction is the free fraction, which is not typically measured in serum, and the majority is metabolized via the kynurenine pathway.\textsuperscript{40} Herein, I-3-L, 4-quinolonecarboxylic acid, and trigonelline were the only tryptophan-related metabolites that were changed following nitisinone treatment. Gertsman et al.\textsuperscript{21} also demonstrated an increase in plasma I-3-L, but additionally indole-3-pyruvate (I-3-P). It has been proposed that the increased activity in the indole pyruvate pathway results from tryptophan aminotransferase having a higher affinity for tryptophan in the presence of keto acids (eg, 4-HPPA, 4-HPLA).\textsuperscript{41} The reason for not observing I-3-P is uncertain, however one may speculate that I-3-L and not I-3-P was increased due to reaction conditions favoring its formation. In addition, differences may in part be explained by different approaches to sample preparation, chromatographic and MS conditions, patient cohorts, and nitisinone doses used. In addition, a separate study showed urinary xanthurenic acid, and L-kynurenine and indoxyl sulfate were increased and decreased following nitisinone therapy, respectively.\textsuperscript{19} The significance of these changes is unknown.

Beyond tryptophan metabolism, there are limited reports on the off target effects of nitisinone on the metabolome. Herein, we have shown that trans-4-hydroxyproline decreases significantly following treatment. This is of particular relevance to AKU as it suggests that there may be decreased collagen breakdown. This requires further investigation as previous authors\textsuperscript{42} have demonstrated a very low cartilage turnover state in AKU patients. In contrast, a different study reported that cartilage degradation, as well as bone resorption markers were elevated in AKU patients compared to controls.\textsuperscript{43}

In addition, significant decreases were observed in the purine and pyrimidine precursors inosine and uridine, respectively. In a previous study, decreased excretion of the purine metabolites adenine and allantoin were reported in urine from AKU patients and AKU mice treated with nitisinone.\textsuperscript{19} Patients included in this study and previous\textsuperscript{19} were not on uric acid-lowering medication, however were on a protein-restricted diet which may contribute to this change. A plausible explanation for the observations in serum and in urine may also relate to changes in the oxidative state of the cell. Allantoin has previously been suggested as a marker of oxidative stress,\textsuperscript{44} one may postulate that the decreases observed in purine and
pyrimidine metabolites are a reflection of reduced oxidative stress in the face of lower HGA concentrations.44

Four unrelated entities were also shown to be decreased following nitisinone therapy: glycocholate, homoserine, mevalonolactone, and allothreonine. The reasons for this remain of unknown significance and require further investigation.

It is important to highlight several limitations in this study. First, while the number of patients included in this study is the largest reported to date, metabolites identified need validating in a larger cohort of patients. Moreover, an untreated group of AKU patients would provide greater credibility that the findings presented herein are a consequence of nitisinone therapy. In addition, while we believe the AMRT database used in this study is comprehensive, the targeted evaluation of the serum metabolome precludes the identification of novel changes in metabolites. Furthermore, the use of nonselective sample preparation to gain broad coverage of the metabolome may have limited metabolite detection if present at a low concentration or if changes were not reproducible due to ion suppression.

9 CONCLUSIONS

Evaluation of the impact of nitisinone treatment on the serum metabolome of patients with AKU revealed a number of novel changes including a number that are not directly related to the tyrosine metabolic pathway. Some of these changes can be explained by the impact of nitisinone therapy on the cellular redox state and the wider impact of metabolites on enzyme activity. Further work is required to provide greater insight into the changes observed in the serum metabolome following nitisinone therapy.

ACKNOWLEDGMENTS

Andrew S. Davison is funded through a National Institute for Health Research (NIHR) Doctoral Research Fellowship (grant code: HCS DRF-2014-05-009). This article presents independent research funded by NIHR. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care.

AUTHOR CONTRIBUTIONS

A.S.D. and B.P.N. conceived, designed and performed research, analyzed data, and wrote the first draft of the article. A.M.M., G.A.R., A.T.H., M.K., J.A.G., and L.R.R. were involved in designing the research and reviewed the manuscript. A.S.D. is the guarantor and corresponding author for this work.

CONFLICT OF INTEREST

The authors declare no potential conflict of interest.

COMPLIANCE WITH ETHICS GUIDELINES

All procedures reported in this review were in accordance with the ethical standards of the local Hospital ethics committee and with the Helsinki Declaration of 1975, as revised in 2000. Analysis of the samples from patients attending the National Alkaptonuria Centre and all subsequent data analysis have been approved by the Royal Liverpool and Broadgreen University Hospital Trust Audit Committee (Audit no. ACO3836).

ORCID

Andrew S. Davison https://orcid.org/0000-0001-5501-4475

REFERENCES

1. Phornphutkul C, Introne WJ, Perry MB, et al. Natural history of alkaptonuria. N Engl J Med. 2002;347:2111-2121.
2. Ranganath LR, Jarvis JC, Gallagher JA. Recent advances in management of alkaptonuria. J Clin Pathol. 2013;66:367-373.
3. Preston AJ, Keenan CM, Sutherland H, et al. Ochronotic ostearthropathy in a mouse model of alkaptonuria, and its inhibition by nitisinone. Ann Rheum Dis. 2014;73:284-289.
4. Introne WJ, Perry MB, Troendle J, et al. A 3-year randomized therapeutic trial of nitisinone in alkaptonuria. Mol Genet Metab. 2011;103:307-314.
5. Milan AM, Hughes AT, Davison AS, et al. The effect of nitisinone on homogentisic acid and tyrosine: a two-year survey of patients attending the National Alkaptonuria Centre, Liverpool. Ann Clin Biochem. 2017;54:323-330.
6. Ranganath LR, Khedr M, Milan AM, et al. Nitisinone arrests ochronosis and decreases rate of progression of alkaptonuria: evaluation of the effect of nitisinone in the United Kingdom National Alkaptonuria Centre. Mol Genet Metab. 2018;125:127-134.
7. Ranganath LR, Milan AM, Hughes AT, et al. Suitability of nitisinone in alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment. Ann Rheum Dis. 2016;75:362-367.
8. Suwannarat P, O'Brien K, Perry MB, et al. Use of nitisinone in patients with alkaptonuria. Metabolism. 2005;54:719-728.
9. Davison AS, Norman BP, Smith EA, et al. Serum amino acid profiling in patients with alkaptonuria before and after treatment with nitisinone. JIMD Rep. 2018a;41:109-117.
10. Olsson B, Cox TF, Faselli EE, et al. Relationship between serum concentrations of nitisinone and its effect on homogentisic acid and tyrosine in patients with alkaptonuria. JIMD Rep. 2015;24:21-27.
11. Lindstedt S, Holme E, Lock EA, et al. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet. 1992;340:813-817.
12. Lock EA. From weed killer to wonder drug. Adv Exp Med Biol. 2017;959:175-185.
13. van Ginkel WG, Jahja R, Huijbregts SCJ, van Sproons FJ. Neurological and neuropsychological problems in tyrosinemia type I patients. Adv Exp Med Biol. 2017;959:111-122.
14. McKiernan PJ, Preece MA, Chakrapani A. Outcome of children with hereditary tyrosinaemia following newborn screening. Arch Dis Child. 2015;100:738-741.

15. Thimm E, Herebian D, Assmann B, Klee D, Mayatepek E, Spiekerkoetter U. Increase of CSF tyrosine and impaired serotonin turnover in tyrosinemia type I. Mol Genet Metab. 2011;102:122-125.

16. Davison AS, Norman B, Milan AM, et al. Assessment of the effect of once daily nitisinone therapy on 24-h urinary metadrenalines and 5-hydroxyindole acetic acid excretion in patients with alkaptonuria after 4 weeks of treatment. JIMD Rep. 2018b;41:1-10.

17. Davison AS, Harrold JA, Hughes G, et al. Clinical and biochemical assessment of depressive symptoms in patients with alkaptonuria before and after two years of treatment with nitisinone. Mol Genet Metab. 2018c;125:135-143.

18. Hillgartner MA, Coker SB, Koenig AE, Moore ME, Barnby E, MacGregor GG. Tyrosinemia type I and not treatment with NTBC causes slower learning and altered behavior in mice. J Inherit Metab Dis. 2016;39:673-682.

19. Norman BP, Davison AS, Ross GA, et al. A comprehensive LC-QTOF-MS metabolic phenotyping strategy: application to alkaptonuria. Clin Chem. 2019;65(4):530-539.

20. Gertsman I, Barshop BA, Panyard-Davis J, et al. Metabolic effects of increasing doses of nitisinone in the treatment of alkaptonuria. JIMD Rep. 2015a;24:13-20.

21. Gertsman I, Gangoiti JA, Nyhan WL, Barshop BA. Perturbations of tyrosine metabolism promote the indolepyruvate pathway via tryptophan in host and microbiome. Mol Genet Metab. 2015b;114:431-437.

22. Vorkas PA, Isaac G, Anwar MA, et al. Untargeted UPLC-MS profiling pipeline to expand tissue metabolome coverage: application to cardiovascular disease. Anal Chem. 2015;87:4814-4819.

23. Griffith OW, Bridges RJ, Meister A. Transport of gamma-glutamyl amino acids: role of glutathione and gamma-glutamyl transpeptidase. Proc Natl Acad Sci U S A. 1979;76:6319-6322.

24. Zhang H, Forman HJ. Redox regulation of γ-glutamyl transpeptidase. Am J Respir Cell Mol Biol. 2009;41:509-515.

25. Davison AS, Milan AM, Gallagher JA, Ranganath LR. Acute fatal metabolic complications in alkaptonuria. J Inherit Metab Dis. 2016;39:203-210.

26. Bracconi D, Bianchini C, Bernardini G, et al. Redox- proteomics of the effects of homogentisic acid in an in vitro human serum model of alkaptonuric ochronosis. J Inherit Metab Dis. 2011;34:1163e-76.

27. Bracconi D, Laschi M, Taylor AM, et al. Proteomic and redox-proteomic evaluation of homogentisic acid and ascorbic acid effects on human articular chondrocytes. J Cell Biochem. 2010;111:922e32.

28. Millucci L, Ghezzi L, Paccagnini E, et al. Amyloidosis, inflammation, and oxidative stress in the heart of an alkaptonuric patient. Mediators Inflamm. 2014;2014:258471.

29. Bracconi D, Millucci L, Bernardini G, Santucci A. Oxidative stress and mechanisms of ochronosis in alkaptonuria. Free Radic Biol Med. 2015;88:70-80.

30. Macsai MS, Schwartz TL, Hinkle D, Hummel MB, Mulhern MG, Rootman D. Tyrosinemia type II: nine cases of ocular signs and symptoms. Am J Ophthalmol. 2001;132:522-527.

31. Hoffer LJ, Sher K, Saboohi F, Bernier P, MacNamara E, Rinzler D. N-acetyl-L-tyrosine as a tyrosine source in adult parental nutrition. J Parenter Enteral Nutr. 2003;27:419-422.

32. Liu G, Cao W, Fang T, et al. Urinary metabolomics approach provides new insights into distinct metabolic profiles of glutamine and N-carbamylglutamate supplementation in rats. Nutrients. 2016;8:478.

33. Kang CW, Han YE, Kim J, Oh JH, Cho YH, Lee EJ. 4-Hydroxybenzaldehyde accelerates acute wound healing through activation of focal adhesion signalling in keratinocytes. Sci Rep. 2017;7(1):14192.

34. Kong BS, Cho YH, Lee EJ. G protein-coupled estrogen Receptor-1 is involved in the protective effect of protocatechuic aldehyde against endothelial dysfunction. PLoS One. 2014;9:e113242.

35. Lee HJ, Seo M, Lee EJ. Salvianolic acid B inhibits atherogenesis of vascular cells through induction of Nrf2-dependent heme oxygenase-1. Curr Med Chem. 2014;21:3095-3106.

36. Lee J-H, Thanigaimalai P, Lee K-C, et al. Novel Benzo[d]imidazole-2(3H)-thiones as potent inhibitors of the α-melanocyte stimulating hormone induced melanogenesis in melanoma B16 cells. Chem Pharm Bull. 2010;58:918-921.

37. Moon CY, Ku CR, Cho YH, Lee EJ. Protocatechuic aldehyde inhibits migration and proliferation of vascular smooth muscle cells and intravascular thrombosis. Biochem Biophys Res Comm. 2012;423:116-121.

38. Rampini S, Völlmin JA, Bosshard HR, Müller M, Curtius HC. Aromatic acids in urine of healthy infants, persistent hyperphenylalaninemia, and phenylketonuria, before and after phenylalanine load. Pediatr Res. 1974;8:704-709.

39. Lynch JJ, Van Vleet TR, Mittelstadt SW, Blomme EAG. Potential functional and pathological side effects related to off-target pharmacological activity. J Pharmacol Toxicol Methods. 2017:87:108-126.

40. Cervenka I, Agudelo LZ, Ruas JL. Kynurenines: Tryptophan's metabolites in exercise, inflammation, and mental health. Science. 2017;357:eaaf9794.

41. Lees GJ, Weiner N. Transaminations between amino acids and keto acids elevated in phenylketonuria and maple syrup urine disease. J Neurochem. 1973:20:389-403.

42. Taylor AM, Hsueh M-F, Ranganath LR, et al. Cartilage biomarkers in the osteoarthropathy of alkaptonuria reveal low turnover and accelerated ageing. Rheumatology. 2017;56:156-164.

43. Genovese F, Siebuhr AS, Musa K, et al. Investigating the robustness and diagnostic potential of extracellular matrix remodelling biomarkers in alkaptonuria. JIMD Rep. 2015;24:29-37.

44. Marrocco I, Altieri F, Peluso I. Measurement and clinical significance of biomarkers of oxidative stress in humans. Oxid Med Cell Longev. 2017;2017:6501046.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of this article.